XML 33 R23.htm IDEA: XBRL DOCUMENT v3.2.0.727
Collaboration and License Agreements, Boehringer Ingelheim International GmbH (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended
Oct. 31, 2010
USD ($)
Molecule
Jun. 30, 2015
USD ($)
Jun. 30, 2014
USD ($)
Jun. 30, 2015
USD ($)
Payment
Jun. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
License And Collaboration Agreements [Line Items]            
Deferred revenue included in current liabilities   $ 10,186   $ 10,186   $ 14,248
Deferred revenue included in long-term liabilities   12,722   $ 12,722   16,472
Boehringer [Member]            
License And Collaboration Agreements [Line Items]            
Collaboration agreement date       October 2010    
Maximum Number Of Molecules To Be Developed And Commercialized As Per Collaboration | Molecule 10          
Non-refundable upfront payment $ 15,000          
Number of annual maintenance payments received | Payment       3    
Additional Potential Clinical Milestone Payments Under Agreement   41,000   $ 41,000    
Additional Potential Regulatory Milestone Payments Under Agreement   89,000   89,000    
Additional Potential Sales Milestone Payments Under Agreement   $ 83,000   $ 83,000    
Research obligation completion date       September 2015    
Clinical milestone payments under agreement            
Recognized revenue under agreement   $ 2,600 $ 3,000 $ 5,200 $ 6,000  
Deferred revenue   2,300   2,300   5,800
Deferred revenue included in current liabilities   2,300   2,300   5,800
Deferred revenue included in long-term liabilities   $ 0   $ 0   $ 0
Milestone payment